See more : Uniparts India Limited (UNIPARTS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhuhai Rundu Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- FREYR Battery, Inc. WT (FREY-WT) Income Statement Analysis – Financial Results
- YanGuFang International Group Co., Ltd. (YGF) Income Statement Analysis – Financial Results
- Rubix Resources Limited (RB6.AX) Income Statement Analysis – Financial Results
- Tethys Oil AB (publ) (0A1V.L) Income Statement Analysis – Financial Results
- BW Energy Limited (BWEFF) Income Statement Analysis – Financial Results
Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rdpharma.cn
About Zhuhai Rundu Pharmaceutical Co., Ltd.
Zhuhai Rundu Pharmaceutical Co., Ltd., a pharmaceutical company, develops, produces, and markets pharmaceutical ingredients for cardiovascular, gastrointestinal, CNS, and anesthesia areas in China and internationally. It offers APIs, intermediates, FDF, and pellets, as well as formulations in the forms of capsules, tablets, and injections. The company was founded in 1997 and is headquartered in Zhuhai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.29B | 1.37B | 1.19B | 1.25B | 1.36B | 1.04B | 779.42M | 651.86M | 577.94M | 523.60M | 434.13M | 361.93M | 311.18M |
| Cost of Revenue | 685.03M | 600.79M | 458.84M | 460.88M | 379.96M | 260.26M | 275.66M | 235.11M | 194.67M | 174.07M | 145.71M | 131.00M | 102.31M |
| Gross Profit | 606.86M | 771.44M | 731.09M | 791.75M | 979.94M | 783.60M | 503.76M | 416.75M | 383.27M | 349.53M | 288.42M | 230.94M | 208.87M |
| Gross Profit Ratio | 46.97% | 56.22% | 61.44% | 63.21% | 72.06% | 75.07% | 64.63% | 63.93% | 66.32% | 66.75% | 66.44% | 63.81% | 67.12% |
| Research & Development | 129.44M | 95.59M | 92.14M | 102.47M | 114.54M | 66.02M | 44.69M | 30.05M | 18.63M | 16.12M | 12.94M | 11.52M | 0.00 |
| General & Administrative | 77.88M | 23.60M | 15.24M | 52.30M | 50.99M | 25.29M | 17.80M | 12.54M | 15.71M | 12.57M | 32.79M | 30.46M | 57.64M |
| Selling & Marketing | 314.63M | 389.55M | 416.65M | 440.99M | 661.57M | 563.77M | 311.94M | 261.63M | 248.26M | 233.68M | 183.76M | 133.57M | 106.17M |
| SG&A | 391.78M | 413.15M | 431.89M | 493.29M | 712.56M | 589.06M | 329.74M | 274.16M | 263.97M | 246.25M | 216.55M | 164.03M | 163.80M |
| Other Expenses | 0.00 | 44.29M | 47.28M | 36.51M | 23.29M | -125.79K | -2.15M | 15.65M | 4.56M | 5.62M | 8.98M | 7.35M | 3.21M |
| Operating Expenses | 566.86M | 553.04M | 571.31M | 632.26M | 850.39M | 674.31M | 390.60M | 326.90M | 301.75M | 279.82M | 222.61M | 169.02M | 168.09M |
| Cost & Expenses | 1.21B | 1.15B | 1.03B | 1.09B | 1.23B | 934.58M | 666.26M | 562.02M | 496.42M | 453.89M | 368.32M | 300.02M | 270.40M |
| Interest Income | 2.25M | 1.35M | 1.91M | 2.49M | 1.30M | 1.62M | 745.26K | 766.32K | 321.06K | 398.48K | 1.34M | 751.90K | -0.44 |
| Interest Expense | 17.24M | 6.97M | 1.77M | 1.77M | 1.99M | 3.10M | 5.11M | 3.92M | 1.95M | 2.26M | 0.00 | 0.00 | 885.62K |
| Depreciation & Amortization | 117.53M | 78.07M | 72.65M | 61.26M | 45.70M | 35.74M | 35.45M | 1.72M | 16.37M | 13.60M | 7.95M | 3.79M | 1.64M |
| EBITDA | 220.80M | 266.43M | 227.02M | 200.58M | 182.03M | 151.82M | 143.17M | 107.28M | 101.15M | 85.34M | 68.87M | 63.55M | 41.23M |
| EBITDA Ratio | 17.09% | 21.32% | 18.62% | 16.49% | 12.91% | 14.54% | 17.88% | 19.42% | 17.70% | 17.06% | 15.86% | 17.56% | 13.25% |
| Operating Income | 86.27M | 181.35M | 153.78M | 153.58M | 133.55M | 119.84M | 103.96M | 85.71M | 78.37M | 64.17M | 60.92M | 59.76M | 39.59M |
| Operating Income Ratio | 6.68% | 13.22% | 12.92% | 12.26% | 9.82% | 11.48% | 13.34% | 13.15% | 13.56% | 12.26% | 14.03% | 16.51% | 12.72% |
| Total Other Income/Expenses | -226.82K | -414.48K | -2.05M | -4.72M | -1.11M | 8.05M | -2.15M | 15.21M | 1.30M | 5.31M | 8.91M | 6.92M | 3.06M |
| Income Before Tax | 86.04M | 180.94M | 151.74M | 148.83M | 132.44M | 119.72M | 101.81M | 100.93M | 82.83M | 69.48M | 69.83M | 66.69M | 42.65M |
| Income Before Tax Ratio | 6.66% | 13.19% | 12.75% | 11.88% | 9.74% | 11.47% | 13.06% | 15.48% | 14.33% | 13.27% | 16.09% | 18.42% | 13.70% |
| Income Tax Expense | 19.14M | 25.46M | 11.97M | 12.97M | 13.55M | 12.87M | 11.16M | 13.46M | 11.66M | 9.96M | 10.47M | 10.09M | 10.43M |
| Net Income | 66.90M | 155.48M | 139.77M | 135.86M | 118.90M | 106.84M | 90.65M | 87.47M | 71.17M | 59.52M | 59.36M | 56.60M | 32.21M |
| Net Income Ratio | 5.18% | 11.33% | 11.75% | 10.85% | 8.74% | 10.24% | 11.63% | 13.42% | 12.31% | 11.37% | 13.67% | 15.64% | 10.35% |
| EPS | 0.20 | 0.46 | 0.42 | 0.41 | 0.36 | 0.33 | 0.37 | 0.36 | 0.29 | 0.24 | 0.24 | 0.23 | 0.13 |
| EPS Diluted | 0.20 | 0.46 | 0.42 | 0.41 | 0.36 | 0.32 | 0.37 | 0.36 | 0.29 | 0.24 | 0.24 | 0.23 | 0.13 |
| Weighted Avg Shares Out | 334.49M | 334.87M | 334.70M | 334.15M | 330.89M | 327.60M | 245.01M | 244.90M | 245.40M | 246.82M | 246.15M | 247.21M | 245.41M |
| Weighted Avg Shares Out (Dil) | 334.49M | 334.87M | 334.70M | 334.15M | 330.89M | 329.59M | 245.03M | 244.90M | 245.41M | 246.82M | 246.15M | 247.21M | 245.41M |
Source: https://incomestatements.info
Category: Stock Reports